Patents by Inventor Rachida Siham Bel Aiba
Rachida Siham Bel Aiba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190345207Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: ApplicationFiled: January 18, 2018Publication date: November 14, 2019Inventors: Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
-
Publication number: 20190338002Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.Type: ApplicationFiled: July 8, 2019Publication date: November 7, 2019Inventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
-
Publication number: 20190309037Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: April 19, 2019Publication date: October 10, 2019Inventors: Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
-
Patent number: 10400016Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.Type: GrantFiled: December 7, 2016Date of Patent: September 3, 2019Assignee: PIERIS PHARMACEUTICALS GMBHInventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
-
Patent number: 10273275Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: May 18, 2016Date of Patent: April 30, 2019Inventors: Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
-
Publication number: 20190031729Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: ApplicationFiled: July 15, 2016Publication date: January 31, 2019Applicant: PIERIS PHARMACEUTICALS GMBHInventors: Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Rachida Siham BEL AIBA, Shane OLWILL, Timo EICHNER
-
Publication number: 20190010231Abstract: The disclosure provides a fusion polypeptide specific for both immune checkpoints PD-1 and LAG-3, whereby the fusion polypeptide can be useful for generating a durable anti-tumor or anti-infection response. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors, or as anti-infection agents. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.Type: ApplicationFiled: August 8, 2016Publication date: January 10, 2019Applicant: Pieris Pharmaceuticals GmbHInventors: Christine ROTHE, Rachida Siham BEL AIBA, Shane OLWILL, Sven BERGER
-
Publication number: 20180334499Abstract: The disclosure provides fusion polypeptides comprising a moiety specific for Ang-2 and another for VEGF-A, which fusion polypeptide can be useful for antagonizing Ang-2 and VEGF-A. In a preferred embodiment, the Ang-2-specific moiety is comprised of a human neutrophil gelatinase associated lipocalin (hNGAL) mutein. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as an agent useful to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making the fusion polypeptides described herein as well as compositions comprising such fusion polypeptides. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptides, their amino acid sequences and to methods for the generation of such fusion polypeptides and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.Type: ApplicationFiled: November 30, 2016Publication date: November 22, 2018Inventors: Shane Olwill, Rachida-Siham Bel Aiba, Alexander Wiedenmann
-
Publication number: 20180148484Abstract: The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: ApplicationFiled: May 4, 2016Publication date: May 31, 2018Applicant: Pieris Pharmaceuticals GmbHInventors: Marlon HINNER, Christine ROTHE, Shane OLWILL, Andrea ALLERSDORFER, Rachida Siham BEL AIBA
-
Publication number: 20180141988Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: May 18, 2016Publication date: May 24, 2018Applicant: Pieris Pharmaceuticals GmbHInventors: Marlon HINNER, Andrea ALLERSDORFER, Rachida Siham BEL AIBA, Michaela ALOE, Alexander WIEDENMANN, Gabriele MATSCHINER, Martin HUELSMEYER
-
Publication number: 20180016312Abstract: The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.Type: ApplicationFiled: January 27, 2016Publication date: January 18, 2018Applicant: Pieris Pharmaceuticals GmbHInventors: Rachida Siham BEL AIBA, Andrea ALLERSDORFER, Alexander WIEDENMANN, Christine ROTHE, Shane OLWILL, Hendrik GILLE, Laurent Audoly
-
Publication number: 20170369542Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: July 7, 2017Publication date: December 28, 2017Applicant: PIERIS PHARMACEUTICALS GMBHInventors: Stefan TRENTMANN, Gabriele MATSCHINER, Arne SKERRA, Andreas HOHLBAUM, Martin HUELSMEYER, Hendrik GILLE, Hans-Juergen CHRISTIAN, Kristian JENSEN, Rachida Siham BEL AIBA
-
Publication number: 20170173112Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: February 28, 2017Publication date: June 22, 2017Applicant: Daiichi Sankyo Co., Ltd.Inventors: Gabriele MATSCHINER, Christine ROTHE, Andreas HOHLBAUM, Andrea ALLERSDORFER, Rachida Siham Bel AIBA, Marlon HINNER, Alexander WIEDENMANN, Bradley LUNDE, Shinji YAMAGUCHI, Takahide ABURATANI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Chikako NAGASAKI, Futoshi NARA, Tomohiro NISHIZAWA
-
Publication number: 20170166615Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.Type: ApplicationFiled: December 7, 2016Publication date: June 15, 2017Applicant: Daiichi Sankyo Co., Ltd.Inventors: GABRIELE MATSCHINER, Christine ROTHE, Alexander WIEDENMANN, Rachida Siham BEL AIBA, Marlon HINNER, Andrea ALLERSDORFER, Bradley LUNDE, Kazufumi KUBOTA, Mitsuhiro MAKINO, Sakiko TAKAHASHI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Mamoru OTOYO
-
Patent number: 9598476Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: GrantFiled: August 28, 2015Date of Patent: March 21, 2017Assignee: Daiichi Sankyo Co., Ltd.Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Publication number: 20160024161Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: August 28, 2015Publication date: January 28, 2016Applicant: Daiichi Sankyo Co., Ltd.Inventors: Gabriele MATSCHINER, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Publication number: 20150369821Abstract: The present invention relates to lipocalin-mutein assays for measuring hepcidin concentration as well as methods preparing and utilizing and kits leveraging the lipocalin-mutein assays.Type: ApplicationFiled: February 5, 2014Publication date: December 24, 2015Applicant: PIERIS AGInventors: Stefan TRENTMANN, Rachida SIHAM BEL AIBA, Andrea ALLERSDORFER, Nicole ANDERSEN, Andreas HOHLBAUM
-
Publication number: 20150291675Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: May 6, 2015Publication date: October 15, 2015Applicant: PIERIS AGInventors: STEFAN TRENTMANN, GABRIELE MATSCHINER, ARNE SKERRA, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, HENDRIK GILLE, HANS-JUERGEN CHRISTIAN, KRISTIAN JENSEN, RACHIDA SIHAM BEL AIBA
-
Patent number: 9150629Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: GrantFiled: March 13, 2014Date of Patent: October 6, 2015Assignee: DAIICHI SANKYO CO., LTD.Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Patent number: 9051382Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: GrantFiled: August 16, 2011Date of Patent: June 9, 2015Assignee: PIERIS AGInventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba